TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism
Brief Summary: The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the occurrence and the recurrence of DVT or pulmonary embolism (PE) in Japanese patients with acute symptomatic DVT without symptomatic PE.


Options:
A: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
C: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism
Brief Summary: The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the occurrence and the recurrence of DVT or pulmonary embolism (PE) in Japanese patients with acute symptomatic DVT without symptomatic PE.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 4
B: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects
Brief Summary: To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.


Options:
A: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: OTHER; Name: Diet Only; Assigned to Arm(s): Evolocumab, Placebo
B: Arm Label: Alirocumab 75 mg/up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), Drug: alirocumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LMT (atorvastatin, simvastatin, or rosuvastatin); Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: alirocumab; Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PETS-D (Parent Education Thru Simulation-Diabetes)
Brief Summary: Hypothesis: Parents who receive Parent Education Thru Simulation-Diabetes (PETS-D) will have significantly higher diabetes knowledge (cognitive visual schemata), better technical and problem-solving competence and confidence, and lower fear and stress/anxiety levels; and provide better diabetes management at 14 weeks compared to those parents receiving standard diabetes education.


Options:
A: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving
B: Arm Label: Education with simulator; Type: EXPERIMENTAL; Interventions: Behavioral: Parent education with human patient simulator | Arm Label: Control arm: standard diabetes education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Parent education with human patient simulator; Assigned to Arm(s): Education with simulator | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Control arm: standard diabetes education
C: Arm Label: Active Comparator: Internet Resources Comparison (IRC); Type: EXPERIMENTAL; Interventions: Behavioral: Internet Resources Comparison (IRC) | Arm Label: I-InTERACT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) | Arm Label: I-InTERACT Express; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express) | Intervention Type: BEHAVIORAL; Name: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT); Assigned to Arm(s): I-InTERACT | Intervention Type: BEHAVIORAL; Name: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express); Assigned to Arm(s): I-InTERACT Express | Intervention Type: BEHAVIORAL; Name: Internet Resources Comparison (IRC); Assigned to Arm(s): Active Comparator: Internet Resources Comparison (IRC)
D: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Two Parenting Programs for At-Risk Families
Brief Summary: The purpose of this study is to compare the effectiveness of two parenting programs in a mental health clinic serving young children with behavior problems.


Options:
A: Arm Label: Intervention Chicago Parent Program arm; Type: EXPERIMENTAL; Interventions: Behavioral: Chicago Parent Program | Arm Label: Parent-Child Interaction Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parent-Child Interaction Therapy | Intervention Type: BEHAVIORAL; Name: Chicago Parent Program; Assigned to Arm(s): Intervention Chicago Parent Program arm | Intervention Type: BEHAVIORAL; Name: Parent-Child Interaction Therapy; Assigned to Arm(s): Parent-Child Interaction Therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Parenting group | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Parenting group; Assigned to Arm(s): 1
C: Arm Label: Family Startup; Type: EXPERIMENTAL; Interventions: Other: Family Startup (in Danish: Familieiværksætterne) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Family Startup (in Danish: Familieiværksætterne); Assigned to Arm(s): Family Startup
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Incredible Years Program | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Incredible Years Program | Intervention Type: BEHAVIORAL; Name: Incredible Years Program; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.
Brief Summary: In total 50 patients diagnosed with long-segment infrapopliteal arterial disease will be randomized in two groups. The patients randomized in the Drug coated balloons (DCB) study arm will undergo a percutaneous transluminal angioplasty (PTA) with the use of a paclitaxel-coated balloon, while the patients randomized in the drug-eluting stent (DES) study arm will undergo primary stenting using drug-eluting stent(s). The study's primary endpoints will be the 6-month angiographic binary restenosis rate. Secondary endpoints will include the immediate technical success,6-month primary patency, target lesion revascularization and limb salvage and complication rates.


Options:
A: Arm Label: Drug Coated Balloon (DCB) Arm; Type: EXPERIMENTAL; Interventions: Procedure: Paclitaxel coated balloon angioplasty. | Arm Label: Drug Eluting Stents (DES) Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infrapopliteal Primary Drug Eluting Stenting | Intervention Type: PROCEDURE; Name: Paclitaxel coated balloon angioplasty.; Assigned to Arm(s): Drug Coated Balloon (DCB) Arm | Intervention Type: PROCEDURE; Name: Infrapopliteal Primary Drug Eluting Stenting; Assigned to Arm(s): Drug Eluting Stents (DES) Arm
B: Arm Label: Drug Eluting Balloon; Type: EXPERIMENTAL; Interventions: Device: IN.PACT Amphirion | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA | Intervention Type: DEVICE; Name: IN.PACT Amphirion; Assigned to Arm(s): Drug Eluting Balloon | Intervention Type: DEVICE; Name: Standard PTA; Assigned to Arm(s): Standard PTA
C: Arm Label: Laser atherectomy and drug-coated balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Arm Label: Drug eluting Ballon PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Intervention Type: DEVICE; Name: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems; Assigned to Arm(s): Drug eluting Ballon PTA, Laser atherectomy and drug-coated balloon
D: Arm Label: Lutonix Catheter; Type: EXPERIMENTAL; Interventions: Device: Lutonix Catheter | Arm Label: Standard uncoated Balloon Angioplasty Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard uncoated Balloon Angioplasty Catheter | Intervention Type: DEVICE; Name: Lutonix Catheter; Assigned to Arm(s): Lutonix Catheter | Intervention Type: DEVICE; Name: Standard uncoated Balloon Angioplasty Catheter; Assigned to Arm(s): Standard uncoated Balloon Angioplasty Catheter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.
Brief Summary: In total 50 patients diagnosed with long-segment infrapopliteal arterial disease will be randomized in two groups. The patients randomized in the Drug coated balloons (DCB) study arm will undergo a percutaneous transluminal angioplasty (PTA) with the use of a paclitaxel-coated balloon, while the patients randomized in the drug-eluting stent (DES) study arm will undergo primary stenting using drug-eluting stent(s). The study's primary endpoints will be the 6-month angiographic binary restenosis rate. Secondary endpoints will include the immediate technical success,6-month primary patency, target lesion revascularization and limb salvage and complication rates.


Options:
A: Arm Label: Drug Coated Balloon (DCB) Arm; Type: EXPERIMENTAL; Interventions: Procedure: Paclitaxel coated balloon angioplasty. | Arm Label: Drug Eluting Stents (DES) Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infrapopliteal Primary Drug Eluting Stenting | Intervention Type: PROCEDURE; Name: Paclitaxel coated balloon angioplasty.; Assigned to Arm(s): Drug Coated Balloon (DCB) Arm | Intervention Type: PROCEDURE; Name: Infrapopliteal Primary Drug Eluting Stenting; Assigned to Arm(s): Drug Eluting Stents (DES) Arm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Implantation of YUKON Sirolimus-eluting Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Implantation of YUKON Stent (uncoated) | Intervention Type: DEVICE; Name: Implantation of YUKON Sirolimus-eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Implantation of YUKON Stent (uncoated); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: XIENCE V everolimus eluting coronary stent system | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: MULTILINK VISION coronary stent system | Intervention Type: DEVICE; Name: XIENCE V everolimus eluting coronary stent system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: MULTILINK VISION coronary stent system; Assigned to Arm(s): 2
D: Arm Label: balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: balloon angioplasty | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: drug eluting stent | Intervention Type: DEVICE; Name: balloon angioplasty; Assigned to Arm(s): balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting stent; Assigned to Arm(s): Drug eluting stent

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)
Brief Summary: The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in patients with longlasting health problems with no known medical explanation, defined as multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing both pain and other symptoms of bodily distress for patients with BDS. Control conditions are pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.


Options:
A: Arm Label: Amiloride; Type: EXPERIMENTAL; Interventions: Drug: Amiloride | Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Amiloride | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Imipramine treatment; Type: EXPERIMENTAL; Interventions: Drug: Imipramine treatment | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine treatment; Assigned to Arm(s): Imipramine treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran

Answer: B